The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In the previous article, we talked about the history of TypeScript and its alternatives. In this article, we will continue our discussion and talk about the most ...

The latest price target for Replimune Group (NASDAQ:REPL) was reported by BMO Capital on November 3, 2025. The analyst firm set a price target for $11.00 expecting REPL to rise to within 12 months (a ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Following a ~39% drop in the previous session, Replimune (NASDAQ:REPL) shares continued to trade lower on Friday as J.P. Morgan downgraded the stock to Underweight from Neutral, citing further ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...